The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.
The reader should not assume that the information is accurate and complete.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 13F

FORM 13F INFORMATION TABLE

OMB APPROVAL
OMB Number: 3235-0006
Estimated average burden
hours per response: 23.8

COLUMN 1 COLUMN 2 COLUMN 3 COLUMN 4 COLUMN 5 COLUMN 6 COLUMN 7 COLUMN 8
VALUE SHRS OR SH/ PUT/ INVESTMENT OTHER VOTING AUTHORITY
NAME OF ISSUER TITLE OF CLASS CUSIP (x$1000) PRN AMT PRN CALL DISCRETION MANAGER SOLE SHARED NONE
AKOUOS INC COM 00973J101 20,829 1,794,088 SH   DFND 1 0 1,794,088 0
ARCUTIS BIOTHERAPEUTICS INC COM 03969K108 13,594 569,041 SH   DFND 1 0 569,041 0
FUSION PHARMACEUTICALS INC COM 36118A100 12,659 1,598,379 SH   DFND 1 0 1,598,379 0
INOZYME PHARMA INC COM 45790W108 18,441 1,591,154 SH   DFND 1 0 1,591,154 0
KARUNA THERAPEUTICS INC COM 48576A100 104,312 852,708 SH   DFND 1 0 852,708 0
VAXCYTE INC COM 92243G108 35,656 1,405,421 SH   DFND 1 0 1,405,421 0
ALIGOS THERAPEUTICS INC COM 01626L105 13,595 876,548 SH   DFND 1 0 876,548 0
BOLT BIOTHERAPEUTICS INC COM 097702104 23,927 1,891,467 SH   DFND 1 0 1,891,467 0
RALLYBIO CORP COM 75120L100 39,930 2,271,311 SH   DFND 1 0 2,271,311 0